



Attorney Docket No.: 6619.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lotte Bjerre Knudsen

Application No.: 10/726,734

Group Art Unit: To be assigned

Filed: December 3, 2003

Examiner: To be assigned

For: **Combination Treatment Using Exendins and Thiazolidinediones**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith a reference which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the reference may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the reference is "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than the one listed exist or that a search has been conducted.

The reference is listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the reference is also enclosed.

The reference is as follows:


1. WO 00/78333 A2

It is respectfully requested that this reference be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached reference.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Respectfully submitted,

Date: February 24, 2004


Richard W. Bork, Reg. No. 36,459
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE



Attorney Docket No.: 6619.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lotte Bjerre Knudsen

Serial No.: 10/726,734

Group Art Unit: To be assigned

Filed: December 3, 2003

Examiner: To be assigned

For: **Combination Treatment Using Exendins and Thiazolidinediones**

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of Reference

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on February 24, 2004

Rashida Haji
(name of person mailing paper)

Rashida Haji
(signature of person mailing paper)



FORM PTO-1449
(Rev. 2-32)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No. **6619.200-US**

Serial No. **10/726,734**

Applicant **Lotte Bjerre Knudsen**

Filing Date **December 3, 2003**

Group **To be assigned**

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		00/78333 A2	12-28-00	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.